Topics

Articles

By 2026, the first 10 drugs for individuals with Part D coverage—whose medications are mainly used to treat cancer, diabetes, and heart disease—will see discounts off of list prices ranging from 38-79%.

Medicare Unveils Results of First-Round Drug Price Negotiations

Managing partner at Numerof & Associates.

A lack of access could shut out patients in need of maintenance drugs for complex conditions.

Pharmacy Deserts are Becoming a National Problem

Senior Vice President, Market Development, at ConnectiveRx.

What does the legislation mean for patient access leaders, pharma brand       managers, and patient service owners? Industry experts weigh in.


The IRA’s Impact on Patient Hub, Access, and Affordability Programs

Making sense of the accelerating trends and challenges—including store closings, pharmacy deserts, and the rise of polypharmacy.

Who Moved My Prescription? Part V: The Many Layers of Pharmacy Crisis Point

Balancing innovation focus with optimized decision-making.


Biotech’s Achilles’ Heel

Investigators evaluate differences in end-of-life care between Medicare beneficiaries in Medicare Advantage vs. traditional Medicare. 

Does Medicare Properly Cover End-of-Life Care for All Beneficiaries? 

How teamwork among safety-net healthcare providers and pharma can make the difference. 

Improving Cross-Industry Collaboration on Drug Discount Programs 

An economic evaluation study assesses these costs by therapeutic class, while identifying trends in pharma R&D intensity over time. 

Determining Drug Development Costs in the United States

A longitudinal observational study examined whether the program was related to access to hospital-based services, while determining if that association differs by hospital ownership.

The Association Between 340B Program Involvement and Availability of Hospital Services

Podcasts

Mark Bouck discusses PharmAlliance’s latest acquisitions, while reiterating its goals surrounding health economics and outcomes research.

Market Access